This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
by Urmimala Biswas
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Amgen's Q3 Earnings in the Cards: Here's What to Expect
by Zacks Equity Research
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market
by Zacks Equity Research
Zacks spotlights Amazon, Wells Fargo, Amgen, IDT and Village Super Market in its latest Analyst Blog, showcasing diverse growth drivers and risks.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $292.89 in the latest trading session, marking a -1.04% move from the prior day.
Top Research Reports for Amazon.com, Wells Fargo & Amgen
by Mark Vickery
Amazon's AI push, Wells Fargo's post-cap growth, and Amgen's new drug momentum headline Zacks' latest top analyst reports.
Why Amgen (AMGN) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw Amgen (AMGN) settling at $295.98, representing a -1.71% change from its previous close.
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
by Kinjel Shah
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
by Zacks Equity Research
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
by Sundeep Ganoria
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Amgen (AMGN) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Amgen (AMGN) stood at $297.32, denoting a +1.18% move from the preceding trading day.
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
by Zacks Equity Research
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
Why Amgen (AMGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
by Kinjel Shah
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
by Zacks Equity Research
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
Here's Why Amgen (AMGN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
by Kinjel Shah
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.